Literature DB >> 11083851

Characterization of bactericidal immune responses following vaccination with acellular pertussis vaccines in adults.

C L Weingart1, W A Keitel, K M Edwards, A A Weiss.   

Abstract

Sera from six adults, collected before and after acellular pertussis vaccination, and from a placebo control were examined for the ability to elicit two bactericidal immune defenses, (i) antibody-dependent complement-mediated bacterial lysis and (ii) opsonization and phagocytosis by human neutrophils. The samples were chosen based on low preimmunization titers and strong postimmunization responses to various combinations of vaccine antigens. All but two prevaccination samples demonstrated activity indicative of complement-mediated lysis. Preimmunization activity could have been due to prior infection or childhood immunization. Immunization did not result in improved bactericidal activity for any of the individuals, and in two cases immunization caused a statistically significant decrease in complement-mediated lysis. Similarly, opsonization with the postimmunization sera failed to enhance attachment or phagocytosis of bacteria by neutrophils, and one postimmunization sample with a strong response to filamentous hemagglutinin caused an inhibition of phagocytosis that was statistically significant compared to that observed for the no-serum control. In summary, booster immunization of adults with acellular pertussis vaccines was not found to increase bactericidal activity over preimmunization levels. Identifying ways to promote bactericidal immune responses might improve the efficacy of acellular pertussis vaccines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11083851      PMCID: PMC97836          DOI: 10.1128/IAI.68.12.7175-7179.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Bordetella pertussis virulence factors affect phagocytosis by human neutrophils.

Authors:  C L Weingart; A A Weiss
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

2.  Neutralizing antibodies to adenylate cyclase toxin promote phagocytosis of Bordetella pertussis by human neutrophils.

Authors:  C L Weingart; P S Mobberley-Schuman; E L Hewlett; M C Gray; A A Weiss
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

Review 3.  Plasma exudation as a first line respiratory mucosal defence.

Authors:  C G Persson; I Erjefält; U Alkner; C Baumgarten; L Greiff; B Gustafsson; A Luts; U Pipkorn; F Sundler; C Svensson
Journal:  Clin Exp Allergy       Date:  1991-01       Impact factor: 5.018

4.  Adenylate cyclase toxin is critical for colonization and pertussis toxin is critical for lethal infection by Bordetella pertussis in infant mice.

Authors:  M S Goodwin; A A Weiss
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

5.  Lethal infection by Bordetella pertussis mutants in the infant mouse model.

Authors:  A A Weiss; M S Goodwin
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

6.  Pertussis toxin and extracytoplasmic adenylate cyclase as virulence factors of Bordetella pertussis.

Authors:  A A Weiss; E L Hewlett; G A Myers; S Falkow
Journal:  J Infect Dis       Date:  1984-08       Impact factor: 5.226

7.  A regulatory role for interleukin 4 in differential inflammatory responses in the lung following infection of mice primed with Th1- or Th2-inducing pertussis vaccines.

Authors:  P McGuirk; K H Mills
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

8.  Mechanisms and regulation of polymorphonuclear leukocyte and eosinophil adherence to human airway epithelial cells.

Authors:  M A Jagels; P J Daffern; B L Zuraw; T E Hugli
Journal:  Am J Respir Cell Mol Biol       Date:  1999-09       Impact factor: 6.914

Review 9.  Review of the biology of Bordetella pertussis.

Authors:  R Parton
Journal:  Biologicals       Date:  1999-06       Impact factor: 1.856

10.  Placebo-controlled trial of two acellular pertussis vaccines in Sweden--protective efficacy and adverse events. Ad Hoc Group for the Study of Pertussis Vaccines.

Authors: 
Journal:  Lancet       Date:  1988-04-30       Impact factor: 79.321

View more
  13 in total

1.  Growth phase influences complement resistance of Bordetella pertussis.

Authors:  Michael G Barnes; Alison A Weiss
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

2.  Acellular pertussis vaccines and complement killing of Bordetella pertussis.

Authors:  Alison A Weiss; Angela K Patton; Scott H Millen; Swei-Ju Chang; Joel I Ward; David I Bernstein
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

3.  Influence of CR3 (CD11b/CD18) expression on phagocytosis of Bordetella pertussis by human neutrophils.

Authors:  Paula S Mobberley-Schuman; Alison A Weiss
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

4.  Opsonophagocytic activity and other serological indications of Bordetella pertussis infection in military recruits in Norway.

Authors:  Audun Aase; Tove Karin Herstad; Samuel Merino; Kari Torkildsen Brandsdal; Bjørn Peter Berdal; Erja M Aleksandersen; Ingeborg S Aaberge
Journal:  Clin Vaccine Immunol       Date:  2007-05-16

5.  Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activity.

Authors:  Audun Aase; Tove Karin Herstad; Samuel Merino; Merete Bolstad; Synne Sandbu; Hilde Bakke; Ingeborg S Aaberge
Journal:  Clin Vaccine Immunol       Date:  2011-06-15

6.  Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization.

Authors:  Jamie N Sutherland; Christine Chang; Sandra M Yoder; Michael T Rock; Jennifer A Maynard
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

7.  Toward a new vaccine for pertussis.

Authors:  John B Robbins; Rachel Schneerson; Joanna Kubler-Kielb; Jerry M Keith; Birger Trollfors; Evgeny Vinogradov; Joseph Shiloach
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-20       Impact factor: 11.205

8.  Differential in vitro expression of the brkA gene in Bordetella pertussis and Bordetella parapertussis clinical isolates.

Authors:  Paola Stefanelli; Maurizio Sanguinetti; Cecilia Fazio; Brunella Posteraro; Giovanni Fadda; Paola Mastrantonio
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

9.  Pertussis toxin and lipopolysaccharide influence phagocytosis of Bordetella pertussis by human monocytes.

Authors:  L M Schaeffer; A A Weiss
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

10.  Characterization of a key neutralizing epitope on pertussis toxin recognized by monoclonal antibody 1B7.

Authors:  Jamie N Sutherland; Jennifer A Maynard
Journal:  Biochemistry       Date:  2009-12-22       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.